Thiouracil, propylthiouracil, benzylthiouracil

Table   Graphic     exposition period:

Congenital malformations
Adverse outcome VerdictOR 95%CI I2k No. casesNo. exposedpublication bias
All congenital malformations (majors, minors, majors and minors, or unspecified)0.99 [0.80, 1.24]36%10 studies249,61412,690low
Major congenital malformations0.69 [0.45, 1.06]0%5 studies1091,638not evaluable
Genital anomalies1.22 [0.96, 1.54]0%3 studies25,81111,037not evaluable
Respiratory system anomalies1.22 [0.76, 1.96]33%3 studies16,00711,037not evaluable
Urinary malformations1.63 [1.01, 2.62]38%3 studies17,69611,037not evaluable
Eye defects0.44 [0.06, 3.31]0%2 studies2,4841,107not evaluable
Congenital heart defects1.05 [0.84, 1.31]17%3 studies77,56811,037not evaluable
Limb defects1.20 [1.05, 1.37]0%3 studies74,70611,037not evaluable
Severe congenital heart defect1.20 [0.06, 22.67]70%2 studies7391,446not evaluable
Abdominal wall defects1.19 [0.15, 9.65]0%2 studies9261,107not evaluable
Carbimazole embryopathy1.61 [0.92, 2.79]0%3 studies2,24311,423not evaluable
Digestive system anomalies1.47 [0.59, 3.67]40%2 studies12,04510,148not evaluable
Nervous system anomalies1.09 [0.72, 1.65]0%2 studies5,86810,148not evaluable
Syndromes and chromosomal abnormalities0.84 [0.33, 2.12]0%2 studies5,5471,107not evaluable
Ano-rectal atresia and stenosis2.87 [0.24, 33.74]67%2 studies1,0551,413not evaluable
Aortic valve atresia/stenosis3.29 [0.12, 89.46]70%2 studies4941,412not evaluable
Cardiac septal defects--0 study
Ear malformations35.97 [1.72, 751.88]-1 study2218not evaluable
Omphalocele1.29 [0.13, 12.49]0%2 studies1541,446not evaluable
Situs inversus15.05 [1.80, 126.08]0%2 studies271,446not evaluable
Coarctation of aorta7.97 [1.64, 38.62]-1 study1,13714not evaluable
33 non statistically significant endpoints reported in only one study

Growth parameters and prematurity
Adverse outcome VerdictOR 95%CI I2k No. casesNo. exposedpublication bias
preterm (< 37 weeks)1.03 [0.73, 1.46]5%5 studies291832not evaluable
low birth weight (< 2500g)1.41 [1.01, 1.97]0%2 studies185637not evaluable
1 non statistically significant endpoints reported in only one study

Maternal consequences
Adverse outcome VerdictOR 95%CI I2k No. casesNo. exposedpublication bias
Caesarean1.09 [0.31, 3.78]69%2 studies9795not evaluable
3 non statistically significant endpoints reported in only one study

Neonatal disorders
Adverse outcome VerdictOR 95%CI I2k No. casesNo. exposedpublication bias
Goiter1.35 [0.37, 4.94]0%5 studies8167not evaluable
Hypothyroidism (fetal/neonatal)0.97 [0.18, 5.39]0%4 studies3180not evaluable
Hyperthyroidism / Thyrotoxicosis (fetal/neonatal)0.87 [0.12, 6.53]0%3 studies281not evaluable
Neonatal hyperthyrotropinemia3.82 [0.36, 40.91]57%2 studies1586not evaluable
1 non statistically significant endpoints reported in only one study

Intrauterine deaths
Adverse outcome VerdictOR 95%CI I2k No. casesNo. exposedpublication bias
Elective termination of pregnancy1.32 [0.72, 2.42]0%3 studies671,745not evaluable
Early intrauterine death (< 22 weeks)1.24 [0.62, 2.47]58%3 studies3941,745not evaluable
Intrauterine deaths (as a whole)1.23 [0.51, 2.93]0%3 studies25102not evaluable
Perinatal death2.00 [0.17, 23.33]59%2 studies191,630not evaluable
Late intrauterine deaths (> 22 weeks)0.20 [0.01, 6.47]74%2 studies9167not evaluable
Ectopic pregnancy--0 study